CA2507009A1 - Multiple variants of meningococcal protein nmb1870 - Google Patents

Multiple variants of meningococcal protein nmb1870 Download PDF

Info

Publication number
CA2507009A1
CA2507009A1 CA002507009A CA2507009A CA2507009A1 CA 2507009 A1 CA2507009 A1 CA 2507009A1 CA 002507009 A CA002507009 A CA 002507009A CA 2507009 A CA2507009 A CA 2507009A CA 2507009 A1 CA2507009 A1 CA 2507009A1
Authority
CA
Canada
Prior art keywords
seq
protein
composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002507009A
Other languages
English (en)
French (fr)
Inventor
Maurizio Comanducci
Mariagrazia Pizza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9948377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2507009(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA2960687A priority Critical patent/CA2960687A1/en
Publication of CA2507009A1 publication Critical patent/CA2507009A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002507009A 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870 Abandoned CA2507009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2960687A CA2960687A1 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0227346.4A GB0227346D0 (en) 2002-11-22 2002-11-22 741
GB0227346.4 2002-11-22
PCT/IB2003/006320 WO2004048404A2 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2960687A Division CA2960687A1 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870

Publications (1)

Publication Number Publication Date
CA2507009A1 true CA2507009A1 (en) 2004-06-10

Family

ID=9948377

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002507009A Abandoned CA2507009A1 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870
CA2960687A Abandoned CA2960687A1 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2960687A Abandoned CA2960687A1 (en) 2002-11-22 2003-11-21 Multiple variants of meningococcal protein nmb1870

Country Status (18)

Country Link
US (6) US20060251670A1 (enExample)
EP (4) EP2258717A3 (enExample)
JP (3) JP4767540B2 (enExample)
CN (1) CN100381464C (enExample)
AU (1) AU2003288681B2 (enExample)
BR (1) BR0316501A (enExample)
CA (2) CA2507009A1 (enExample)
CY (2) CY1115778T1 (enExample)
DK (3) DK2258716T3 (enExample)
ES (3) ES2436747T5 (enExample)
GB (1) GB0227346D0 (enExample)
HU (1) HUE034257T2 (enExample)
MX (1) MXPA05005442A (enExample)
NZ (1) NZ540206A (enExample)
PT (3) PT1562983E (enExample)
RU (1) RU2336091C2 (enExample)
SI (3) SI1562983T1 (enExample)
WO (1) WO2004048404A2 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
CN101139590B (zh) 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
DE60335477D1 (de) * 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
EP1618185A4 (en) * 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20090104218A1 (en) * 2004-12-22 2009-04-23 J. Craig Venter Institute Group B Streptococcus
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) * 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
NZ595361A (en) 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
CN102740882A (zh) 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
BR112012004275A2 (pt) * 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
EP2493499A1 (en) * 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
JP2013521326A (ja) * 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
AU2011268507B2 (en) * 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
AU2011300409B2 (en) * 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP2014529407A (ja) 2011-08-31 2014-11-13 チルドレンズホスピタル アンド リサーチ センター オークランド ナイセリアにおいて抗原の発現を促進するための操作された配列および使用方法
JP2015505309A (ja) * 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2918547A1 (en) * 2013-08-02 2015-02-05 Peter T. Beernink Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CA2940447C (en) * 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
AR101225A1 (es) * 2014-07-17 2016-11-30 Glaxosmithkline Biologicals Sa Vacunas de meningococos
EA201692552A1 (ru) 2014-07-17 2017-06-30 Глаксосмитклайн Байолоджикалс С.А. МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
EP2977759B1 (en) * 2014-07-25 2017-07-12 Serum Institute of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
BR112017025954A2 (pt) 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
AR104833A1 (es) * 2015-07-01 2017-08-16 Syngenta Participations Ag Composiciones y métodos para controlar plagas de plantas
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
EP3312192B1 (en) * 2016-10-24 2023-02-22 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019126197A1 (en) 2017-12-18 2019-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacterial polysaccharide-conjugated carrier proteins and use thereof
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0063953A3 (en) 1981-04-29 1983-10-19 Biogen N.V. Bacillus cloning vectors, recombinant dna molecules, bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
WO1998017805A2 (en) 1996-10-24 1998-04-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office Invasion associated genes from neisseria meningitidis serogroup b
WO1998018931A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
ATE476508T1 (de) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic Neisseriale antigene
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
BR9814878A (pt) 1997-11-21 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia pneumoniae, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
BR9814912A (pt) 1997-11-28 2000-10-03 Genset Sa Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
SG152917A1 (en) * 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP2261341A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
CN1338005A (zh) 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOMIC SEQUENCE OF CHLAMYDIA PNEUMONIAE
EP1135405A4 (en) * 1998-11-20 2002-10-29 Vincent Guerriero BY DNA-CODED PROTEINS THAT INHIBIT THE FUNCTION OF Hsp70
WO2000032784A1 (en) * 1998-12-01 2000-06-08 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU1540500A (en) * 1998-12-01 2000-06-19 Aventis Pasteur Limited (chlamydia) antigens and corresponding dna fragments and uses thereof
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DE60041042D1 (de) * 1999-03-12 2009-01-22 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
MXPA01011047A (es) 1999-04-30 2003-10-14 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
EP1860191A3 (en) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
EP2275129A3 (en) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
CN101139590B (zh) 2000-02-28 2012-07-18 启龙股份公司 奈瑟球菌蛋白质的杂交表达
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP4799803B2 (ja) * 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN101428006A (zh) 2000-09-28 2009-05-13 诺华疫苗和诊断公司 微粒体组合物及其生产方法
WO2002034771A2 (en) 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
MXPA04000653A (es) 2001-07-27 2004-11-22 Chiron Srl Adhesinas de meningococcus nada, app y orf 40.
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
MXPA04009339A (es) 2002-03-26 2005-01-25 Chiron Srl Sacaridos modificados que tienen estabilidad mejorada en agua.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DE60335477D1 (de) * 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004065603A2 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
EP1618185A4 (en) 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
AU2004240558A1 (en) 2003-05-07 2004-12-02 Aventis Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
ATE506963T1 (de) * 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
DK2682126T3 (en) 2005-01-27 2017-02-27 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
US20100203137A1 (en) 2007-06-04 2010-08-12 Mario Contorni Formulation of meningitis vaccines
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
TWI460857B (zh) * 2007-08-03 2014-11-11 Univ Hong Kong Science & Techn 可靠之常關型iii族－氮化物主動裝置結構，以及相關方法與系統
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2012031271A1 (en) 2010-09-04 2012-03-08 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9427476B2 (en) 2012-05-24 2016-08-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent meningococcal conjugates and methods for preparing conjugates
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с

Also Published As

Publication number Publication date
US20120148617A1 (en) 2012-06-14
NZ540206A (en) 2006-12-22
EP1562983B1 (en) 2013-10-02
JP2006521782A (ja) 2006-09-28
HUE034257T2 (en) 2018-01-29
EP2258716B1 (en) 2014-07-16
CN1732183A (zh) 2006-02-08
CN100381464C (zh) 2008-04-16
JP4767540B2 (ja) 2011-09-07
US10328142B2 (en) 2019-06-25
WO2004048404A2 (en) 2004-06-10
WO2004048404A3 (en) 2004-09-16
EP2261239A3 (en) 2011-01-19
HK1088342A1 (zh) 2006-11-03
US20060251670A1 (en) 2006-11-09
US8980286B2 (en) 2015-03-17
ES2436747T3 (es) 2014-01-07
US20180028641A1 (en) 2018-02-01
GB0227346D0 (en) 2002-12-31
PT2258716E (pt) 2014-10-10
MXPA05005442A (es) 2005-08-26
US20160039887A1 (en) 2016-02-11
JP2013176371A (ja) 2013-09-09
CA2960687A1 (en) 2004-06-10
PT2261239T (pt) 2017-08-14
SI2258716T1 (sl) 2014-09-30
JP5564297B2 (ja) 2014-07-30
US20170290902A1 (en) 2017-10-12
CY1115778T1 (el) 2017-01-25
CY1119019T1 (el) 2018-01-10
EP2258716A2 (en) 2010-12-08
RU2336091C2 (ru) 2008-10-20
US9550814B2 (en) 2017-01-24
EP2261239B1 (en) 2017-05-24
DK1562983T3 (da) 2013-11-11
ES2637065T3 (es) 2017-10-10
SI1562983T1 (sl) 2013-12-31
DK2261239T3 (en) 2017-07-10
EP2258716A3 (en) 2011-01-19
JP2010162038A (ja) 2010-07-29
ES2436747T5 (es) 2018-03-02
SI2261239T1 (sl) 2017-10-30
RU2005119640A (ru) 2006-01-20
BR0316501A (pt) 2005-10-04
EP1562983A2 (en) 2005-08-17
US20120148618A1 (en) 2012-06-14
EP1562983B2 (en) 2017-11-15
AU2003288681B2 (en) 2009-06-04
AU2003288681A1 (en) 2004-06-18
EP2258717A3 (en) 2011-01-26
EP2261239A2 (en) 2010-12-15
DK2258716T3 (da) 2014-10-20
PT1562983E (pt) 2013-12-09
EP2258717A2 (en) 2010-12-08
ES2509915T3 (es) 2014-10-20

Similar Documents

Publication Publication Date Title
US10328142B2 (en) Multiple variants of meningococcal protein NMB1870
US8398999B2 (en) Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870
EP1784419B1 (en) Domains and epitopes of meningococcal protein nmb1870
AU2013201318B2 (en) Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
HK1088342B (en) Multiple variants of meningococcal protein nmb1870
MX2008006719A (es) Polipeptidos quimericos, hibridos y en tandem de meningococos nmb1870

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20190703